[{"id":"fb4d840f-ccf1-4e5e-ac00-2c10191c007e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554367","created_at":"2022-09-26T14:56:10.119Z","updated_at":"2025-02-25T13:54:43.263Z","phase":"Phase 2","brief_title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554367","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • RAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 08/26/2026","primary_completion_date":" 08/26/2026","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2025-02-20"},{"id":"a3c29634-7fe3-458b-95a0-a95c7ed454c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101788","created_at":"2021-01-18T09:42:39.713Z","updated_at":"2025-02-25T16:36:20.602Z","phase":"Phase 2/3","brief_title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02101788","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 02/27/2014","start_date":" 02/27/2014","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 10/11/2025","study_completion_date":" 10/11/2025","last_update_posted":"2025-02-06"},{"id":"577a4268-ea8b-44ef-b557-7019f2e329c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691504","created_at":"2023-01-20T16:00:14.081Z","updated_at":"2025-02-25T16:46:30.558Z","phase":"Phase 1","brief_title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","source_id_and_acronym":"NCT05691504","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • BCL2L1","pipe":"","alterations":" ","tags":["BRAF • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • pelcitoclax (APG-1252)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-05"},{"id":"074f4f72-e179-49af-b9d4-a6b1faee4ca3","acronym":"NRG-GY021","url":"https://clinicaltrials.gov/study/NCT04034927","created_at":"2021-01-18T19:48:04.192Z","updated_at":"2025-02-25T17:00:08.274Z","phase":"Phase 2","brief_title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","source_id_and_acronym":"NCT04034927 - NRG-GY021","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 12/04/2019","start_date":" 12/04/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-03"},{"id":"739976b0-7ec7-4952-93a7-789eca0ef355","acronym":"","url":"https://clinicaltrials.gov/study/NCT05114421","created_at":"2021-11-10T14:12:47.360Z","updated_at":"2025-02-25T17:25:20.145Z","phase":"Phase 2","brief_title":"Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients","source_id_and_acronym":"NCT05114421","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/09/2021","start_date":" 11/09/2021","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-01-31"},{"id":"ec583cea-b73e-4568-91d2-545510d640f1","acronym":"LEPRE","url":"https://clinicaltrials.gov/study/NCT05601700","created_at":"2025-02-25T18:07:59.797Z","updated_at":"2025-02-25T18:07:59.797Z","phase":"Phase 3","brief_title":"Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)","source_id_and_acronym":"NCT05601700 - LEPRE","lead_sponsor":"Ente Ospedaliero Ospedali Galliera","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 09/22/2022","start_date":" 09/22/2022","primary_txt":" Primary completion: 09/22/2029","primary_completion_date":" 09/22/2029","study_txt":" Completion: 09/22/2029","study_completion_date":" 09/22/2029","last_update_posted":"2025-01-27"},{"id":"063a0064-5caa-408a-8c70-d7f6a82b7af1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02953457","created_at":"2021-01-18T14:30:22.179Z","updated_at":"2025-02-25T15:07:19.264Z","phase":"Phase 2","brief_title":"Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation","source_id_and_acronym":"NCT02953457","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/29/2017","start_date":" 06/29/2017","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 08/15/2024","study_completion_date":" 08/15/2024","last_update_posted":"2024-11-19"},{"id":"4f33daa7-3ce5-4186-b28f-85f4758b6b4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01116648","created_at":"2021-01-18T04:25:31.641Z","updated_at":"2025-02-25T16:23:24.150Z","phase":"Phase 1/2","brief_title":"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","source_id_and_acronym":"NCT01116648","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 04/14/2010","start_date":" 04/14/2010","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 02/13/2025","study_completion_date":" 02/13/2025","last_update_posted":"2024-10-31"},{"id":"e0eae0c1-fbd3-4860-8074-47f0db5f46f5","acronym":"CHARGE","url":"https://clinicaltrials.gov/study/NCT04315233","created_at":"2021-01-18T20:54:52.326Z","updated_at":"2025-02-25T15:43:56.139Z","phase":"Phase 1","brief_title":"Ribociclib\u0026Belinostat In Patients w Metastatic Triple Neg Breast Cancer \u0026 Recurrent Ovarian Cancer w Response Prediction By Genomics","source_id_and_acronym":"NCT04315233 - CHARGE","lead_sponsor":"University of Utah","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-10-30"},{"id":"390f3cd2-f31a-4706-82b7-5a2ff1262bf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923934","created_at":"2021-01-17T17:46:27.086Z","updated_at":"2025-02-25T14:36:43.471Z","phase":"Phase 2","brief_title":"A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers","source_id_and_acronym":"NCT02923934","lead_sponsor":"Olivia Newton-John Cancer Research Institute","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 08/22/2017","start_date":" 08/22/2017","primary_txt":" Primary completion: 04/27/2020","primary_completion_date":" 04/27/2020","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2024-07-24"},{"id":"45278662-36a8-4fe3-8690-2d8d82a1f451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05841563","created_at":"2023-05-03T15:04:56.483Z","updated_at":"2024-07-02T16:34:26.037Z","phase":"Phase 1","brief_title":"Clinical Trial of PM54 in Advanced Solid Tumors Patients.","source_id_and_acronym":"NCT05841563","lead_sponsor":"PharmaMar","biomarkers":" BRAF • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • BRAF mutation • BRAF wild-type","tags":["BRAF • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PM54"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-14"},{"id":"9a54d64d-2889-431d-bba8-38823f83de86","acronym":"","url":"https://clinicaltrials.gov/study/NCT05922930","created_at":"2023-06-28T14:08:31.873Z","updated_at":"2024-07-02T16:34:25.851Z","phase":"Phase 1/2","brief_title":"Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer","source_id_and_acronym":"NCT05922930","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • TACSTD2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • TROP2 expression","tags":["BRCA1 • BRCA2 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • TROP2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TROP2-CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-06-14"},{"id":"54a84071-c2ad-487e-b24d-56980071bc66","acronym":"","url":"https://clinicaltrials.gov/study/NCT02068794","created_at":"2021-01-18T09:31:44.594Z","updated_at":"2024-07-02T16:34:26.660Z","phase":"Phase 1/2","brief_title":"MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer","source_id_and_acronym":"NCT02068794","lead_sponsor":"Mayo Clinic","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MV-NIS"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 03/31/2014","start_date":" 03/31/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"1251a894-93e6-4c49-a11d-e5400df1cba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05605509","created_at":"2022-11-04T16:58:13.524Z","updated_at":"2024-07-02T16:34:26.676Z","phase":"Phase 2","brief_title":"RP-6306 in Patients With Advanced Cancer","source_id_and_acronym":"NCT05605509","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • KRAS • TP53 • CCNE1 • UGT1A1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1","tags":["HER-2 • KRAS • TP53 • CCNE1 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-12"},{"id":"013fa224-7354-475f-bf22-774d9ee304d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03675893","created_at":"2021-01-18T18:01:44.633Z","updated_at":"2024-07-02T16:34:27.103Z","phase":"Phase 2","brief_title":"RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer","source_id_and_acronym":"NCT03675893","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole • zotatifin (eFT226) • metformin • samotolisib (LY3023414)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 12/24/2018","start_date":" 12/24/2018","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2024-06-11"},{"id":"413409a2-0792-4de1-a64e-d4d1801140e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586661","created_at":"2021-01-18T17:38:28.376Z","updated_at":"2024-07-02T16:34:27.534Z","phase":"Phase 1","brief_title":"Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03586661","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/29/2019","start_date":" 04/29/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-11"},{"id":"2d2751e6-8b4b-447b-8365-e4c1074e4966","acronym":"NCI-2014-00620","url":"https://clinicaltrials.gov/study/NCT02101775","created_at":"2021-01-18T09:42:38.823Z","updated_at":"2024-07-02T16:34:37.479Z","phase":"Phase 2","brief_title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02101775 - NCI-2014-00620","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • adavosertib (AZD1775) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 02/03/2022","primary_completion_date":" 02/03/2022","study_txt":" Completion: 02/20/2025","study_completion_date":" 02/20/2025","last_update_posted":"2024-06-07"},{"id":"6534f635-d546-46d9-bcee-4922c51c31eb","acronym":"NCI-2014-00620","url":"https://clinicaltrials.gov/study/NCT02151292","created_at":"2021-01-18T10:00:09.514Z","updated_at":"2024-07-02T16:34:37.200Z","phase":"Phase 2","brief_title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02151292 - NCI-2014-00620","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 02/03/2022","primary_completion_date":" 02/03/2022","study_txt":" Completion: 02/20/2025","study_completion_date":" 02/20/2025","last_update_posted":"2024-06-07"},{"id":"f457b6dc-bf69-44d9-a56c-049a2a1cb232","acronym":"","url":"https://clinicaltrials.gov/study/NCT02111941","created_at":"2024-01-03T19:17:22.178Z","updated_at":"2024-07-02T16:34:38.080Z","phase":"Phase 1","brief_title":"Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02111941","lead_sponsor":"Mayo Clinic","biomarkers":" IFNG • TNFA • IL10 • GZMB • IL17A","pipe":"","alterations":" ","tags":["IFNG • TNFA • IL10 • GZMB • IL17A"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 07/27/2021","primary_completion_date":" 07/27/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-05"},{"id":"3d93b394-a76f-412d-8318-5dfa5e8d3b54","acronym":"ENGOT-0V44","url":"https://clinicaltrials.gov/study/NCT03602859","created_at":"2021-01-18T17:42:44.526Z","updated_at":"2024-07-02T16:34:59.099Z","phase":"Phase 3","brief_title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","source_id_and_acronym":"NCT03602859 - ENGOT-0V44","lead_sponsor":"Tesaro, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1402","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 10/25/2024","primary_completion_date":" 10/25/2024","study_txt":" Completion: 06/22/2026","study_completion_date":" 06/22/2026","last_update_posted":"2024-06-04"},{"id":"219d1e0e-b56c-4bab-85c7-f221ec0d5b47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05252390","created_at":"2022-02-23T19:55:04.757Z","updated_at":"2024-07-02T16:35:00.496Z","phase":"Phase 1/2","brief_title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05252390","lead_sponsor":"Nuvation Bio Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868"],"overall_status":"Recruiting","enrollment":" Enrollment 657","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-29"},{"id":"bcad0e5d-8e9a-4e78-8773-942d97532535","acronym":"FUCHSia","url":"https://clinicaltrials.gov/study/NCT03926936","created_at":"2021-01-18T19:20:57.374Z","updated_at":"2024-07-02T16:35:00.857Z","phase":"Phase 2","brief_title":"FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study","source_id_and_acronym":"NCT03926936 - FUCHSia","lead_sponsor":"Frederic Amant","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/27/2022","study_completion_date":" 12/27/2022","last_update_posted":"2024-05-27"},{"id":"4c69c646-417d-429d-bb95-ea9731d61b06","acronym":"COCOS","url":"https://clinicaltrials.gov/study/NCT02502266","created_at":"2021-01-18T12:04:33.243Z","updated_at":"2024-07-02T16:35:02.420Z","phase":"Phase 2/3","brief_title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT02502266 - COCOS","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 562","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-21"},{"id":"b381b68a-4a91-4d7c-be09-25e6dfa54fa6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04575935","created_at":"2021-01-18T21:50:43.217Z","updated_at":"2024-07-02T16:35:02.267Z","phase":"Phase 3","brief_title":"Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial","source_id_and_acronym":"NCT04575935","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-05-21"}]